Insight Molecular Diagnostics Inc. Common Stock (IMDX)
Stock · NASDAQ · Health Care
$3.03as of 10/16/2026
Price chart
Active signals
IMDX Signal Track Record
How signals performed across all stocks →What IMDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | -5.5% | 42% | September 18, 2026 |
| Bollinger Band Breakdown | 24 | -0.9% | 46% | September 16, 2026 |
| Bollinger Band Breakout | 20 | -6.3% | 40% | May 14, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +1.7% | 54% | July 22, 2025 |
| Any 20-session window (baseline) | -5.9% | 34% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMDX
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that asses…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 55
- Website
- imdxinc.com/
Fundamentals
- 1-day range
- $2.79$3.12
- Market cap
- $154.99M
- P/E (trailing)
- —
- P/E (forward)
- -3.82
- EPS (trailing)
- $-1.48
- Dividend yield
- —
- Beta
- 1.87
- Avg. volume
- 228.6K
How Insight Molecular Diagnostics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Insight Molecular Diagnostics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IMDXInsight Molecular Diagnostics Inc. Common Stock$3.01▼ 1.63%Market cap $154.99MP/E —$2.42$8.51
- ICCCImmuCell Corporation Common Stock$10.75▲ 1.80%Market cap $99.70MP/E 121.11$4.52$12.1
- QCLSQ/C Technologies Inc. Common Stock$0.538▼ 3.58%Market cap $21.99MP/E —$0.4201$8.17
- VNRXVolitionRX Limited Common Stock$0.18▼ 5.26%Market cap $9.23MP/E —$0.18$10.31
- TRIBTrinity Biotech plc American Depositary Shares$8.03▲ 1.26%Market cap $7.86MP/E —$5.01$52.5
- MYGNMyriad Genetics Inc. Common Stock$3.98▼ 8.51%Market cap $304.17MP/E —$2.74$8.59
- BMRABiomerica Inc. Common Stock$1.85▼ 1.60%Market cap $4.94MP/E —$1.45$3.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMDX Insight Molecular Diagnostics Inc. Common Stock | $154.99M | — | $3.01 | ▼ 1.63% | $2.42$8.51 |
| ICCC ImmuCell Corporation Common Stock | $99.70M | 121.11 | $10.75 | ▲ 1.80% | $4.52$12.1 |
| QCLS Q/C Technologies Inc. Common Stock | $21.99M | — | $0.538 | ▼ 3.58% | $0.4201$8.17 |
| VNRX VolitionRX Limited Common Stock | $9.23M | — | $0.18 | ▼ 5.26% | $0.18$10.31 |
| TRIB Trinity Biotech plc American Depositary Shares | $7.86M | — | $8.03 | ▲ 1.26% | $5.01$52.5 |
| MYGN Myriad Genetics Inc. Common Stock | $304.17M | — | $3.98 | ▼ 8.51% | $2.74$8.59 |
| BMRA Biomerica Inc. Common Stock | $4.94M | — | $1.85 | ▼ 1.60% | $1.45$3.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Andrew J. Last · July 1, 2026 · Tax Withholding7.7K @ $5.69
- Andrew Arno · July 1, 2026 · Tax Withholding12.1K @ $5.69
- Lou Silverman · July 1, 2026 · Tax Withholding7.7K @ $5.69
- Lou Silverman · June 11, 2026 · Grant26.9K
- Andrew J. Last · June 11, 2026 · Grant26.9K
- Andrew Arno · June 11, 2026 · Grant32.3K
- BROADWOOD PARTNERS, L.P. · April 27, 2026 · Buy0
- BROADWOOD PARTNERS, L.P. · April 27, 2026 · Buy250.9K @ $3.64
- BROADWOOD PARTNERS, L.P. · April 24, 2026 · Buy0
- BROADWOOD PARTNERS, L.P. · April 24, 2026 · Buy38.9K @ $3.53
- BROADWOOD PARTNERS, L.P. · April 23, 2026 · Buy0
- BROADWOOD PARTNERS, L.P. · April 23, 2026 · Buy280.4K @ $3.5
- BROADWOOD PARTNERS, L.P. · April 20, 2026 · Buy0
- BROADWOOD PARTNERS, L.P. · April 20, 2026 · Buy40.7K @ $3.88
- BROADWOOD PARTNERS, L.P. · April 17, 2026 · Buy0
Institutional Ownership
March 31, 2026
- Total shares held
- 18.80M
- Total value held
- $60.85M
- Institutional holders
- 38
- Unknown11.93M
- Unknown2.81M
- Unknown947.1K
- Unknown840.8K
- Unknown537.2K
- Unknown392.5K
- Unknown262.1K
- Unknown247.4K
- Unknown135.3K
- Unknown127.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms
Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.